Clinical trial · Observational
Patient Reported Symptom Control With THC or CBD Use
NCT04875286CI-TRIAL-00104772active not recruitingClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 12, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260912-000001
Summary
Brief summary (as posted)
This study compares patients' attitudes regarding marijuana products for medical use and other treatments for cancer-related pain. This study may help researchers gain better understanding of patient's perception on their use of marijuana products in treating cancer-related pain and other common cancer-related symptoms.
Conditions
Conditions (3)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Cancer-Associated Pain | — | UNRESOLVED | — |
| Hematopoietic and Lymphoid Cell Neoplasm | Hematopoietic and Lymphoid Cell Neoplasm | ONTOLOGY_EXACT | 0.98 |
| Malignant Solid Neoplasm | Malignant Solid Neoplasm | ONTOLOGY_EXACT | 0.98 |
Interventions
Interventions (2)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Electronic Health Record Review | Other | — | UNRESOLVED |
| Questionnaire Administration | Other | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- label
- Observational (medical record review, questionnaires))
- description
- Patients' medical records are reviewed and then complete questionnaires over 27 minutes.
- interventionNames
- Other: Electronic Health Record Review
- Other: Questionnaire Administration
Primary outcomes (1)
- measure
- Proportion of patients who prefer opioids with THC-marijuana and/or opioids with cannabidiol (CBD) to opioids alone for their cancer pain relief
- timeFrame
- through study completion, an average of 1 year
- description
- Will be calculated and reported along with a 95% confidence interval.
Secondary outcomes (8)
- measure
- Perception of cancer-related symptom relief
- timeFrame
- through study completion, an average of 1 year
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * Patients (inpatient or outpatient) seen by the Palliative Care and Integrative Medicine teams at The University of Texas MD Anderson Cancer Center (Texas) and the Palliative Care team at Banner MD Anderson Cancer Center (Arizona) * Patients must be primary residents of Texas or Arizona * Patients able to speak and read English * Patients are 18 years old and above * Patients should have a cancer diagnosis, cancer-associated pain, and taking strong opioids (morphine, oxycodone, hydrocodone, hydromorphone, oxymorphone, methadone, fentanyl) * Patients who have used in the past 3 months or are using alternative botanical pain management while under prescription opioids Exclusion Criteria: * Patients who are not able to speak or read English * Altered mental status as determined by the interviewer based on the ability to understand the nature of the study and consent process * Patients who have not used medical marijuana and/or CBD products * Patients who do not have cancer * Patients who do not have cancer-associated pain * Patients who are not taking opioids
References
Publications (0)
Data not yet available
No reference posted for this study.